MedTrace Logo

Recurrent AA Amyloidosis After Renal Transplantation

NCT02704065 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2017-04-18

No results posted yet for this study

Summary

End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.

Conditions

  • AA Amyloidosis

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Yasar Caliskan, MD · Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704065 on ClinicalTrials.gov